Evaluate the Safety of Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Yeast) in Healthy Females

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
This study will evaluate the safety of a novel recombinant human papillomavirus bivalent ( types 16 and 18 ) vaccine ( Yeast ) with different dose in healthy females between 9-45 years of age at enrollment.
Epistemonikos ID: ed945be9135b1b581546dc40923b30fe8e96df06
First added on: May 10, 2024